Value investing message boards image Log on |  Join ($$) Stock market forums image VF "How To" Guide        Welcome, guest! Learn about guest access                       
ValueForum.com Home
• Related Discussion Forum Messages
As a ValueForum member, this section would contain NBIX message board posts where the ticker symbol NBIX has been mentioned by ValueForum members in posts. Learn more about guest access, and benefits of membership -- we hope you will consider joining ValueForum or trying out our service with a 24 hour trial pass.

• Latest NBIX SEC Filings

Filings Format Description Filing Date File/Film Number
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-17-065019 Size: 8 KB
2017-12-11
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-17-064210 Size: 9 KB
2017-12-06
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-17-063937 Size: 5 KB
2017-12-05
8-K  Documents Current report, item 5.02
Acc-no: 0001193125-17-361613 (34 Act)  Size: 20 KB
2017-12-05 000-22705
171240062
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-17-063918 Size: 7 KB
2017-12-05
3  Documents Initial statement of beneficial ownership of securities
Acc-no: 0001209191-17-063914 Size: 4 KB
2017-12-05
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-17-061486 Size: 9 KB
2017-11-17
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-17-060286 Size: 5 KB
2017-11-13
CT ORDER  Documents Confidential treatment order
Acc-no: 9999999997-17-009799 (34 Act)  Size: 10 KB
2017-11-09 000-22705
171191434
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-17-059434 Size: 16 KB
2017-11-06
More NBIX SEC Filings


Related news from
Wed, 13 Dec 2017
13:03:15 +0000
See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc NASDAQ/NGS:NBIX
Thu, 07 Dec 2017
18:15:00 +0000
Neurocrine Biosciences to Present at the BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference
Live Audio Webcast Will be on December 14, 2017 SAN DIEGO , Dec. 7, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) will present at the BMO Capital Markets 2017 Prescriptions for Success ...
Mon, 04 Dec 2017
21:01:00 +0000
Neurocrine Biosciences Presents Long-term Data Analyses from Open-label KINECT 4 Phase III Study Demonstrating INGREZZA® Improves Tardive Dyskinesia Symptoms
- INGREZZA (valbenazine) Capsules Taken Once-daily Improved Tardive Dyskinesia Symptoms in Patients and was Generally Well Tolerated in 52-week Trial - Additional Data Presented from INGREZZA Clinical ...
Wed, 29 Nov 2017
21:01:00 +0000
Neurocrine Biosciences to Present New Long-Term Data Evaluating INGREZZA® for the Treatment of Tardive Dyskinesia at the American College of Neuropsychopharmacology Annual Meeting
Data from the Open-label KINECT 4 Phase III Study to be Presented as an Oral Hot Topic SAN DIEGO , Nov. 29, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that new long-term ...
Tue, 21 Nov 2017
18:15:00 +0000
Neurocrine Biosciences to Present at the 29th Annual Piper Jaffray Healthcare Conference
Live Audio Webcast Will be on November 28, 2017 SAN DIEGO , Nov. 21, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) will present at the 29th Annual Piper Jaffray Healthcare Conference ...
Tue, 21 Nov 2017
13:15:00 +0000
Detailed Research: Economic Perspectives on Nexstar Broadcasting Group, CECO Environmental, Performance Food Group, Neurocrine Biosciences, e.l.f. Beauty, and Big Lots — What Drives Growth in Today's Competitive Landscape
NEW YORK, Nov. 21, 2017-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Nexstar ...
Mon, 20 Nov 2017
21:01:00 +0000
Neurocrine Biosciences Appoints Matt Abernethy as Chief Financial Officer
SAN DIEGO, Nov. 20, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX), a biotechnology company focused on neurological and endocrine related disorders, today announced that Matt Abernethy is joining the executive management team as Chief Financial Officer (CFO). "We are very pleased to welcome Matt Abernethy to the Neurocrine team as our Chief Financial Officer," said Kevin Gorman, Ph.D., Chief Executive Officer of Neurocrine Biosciences. Abernethy has nearly 15 years of experience in the financial sector and investor relations with expertise in the healthcare industry. He joins Neurocrine from Zimmer Biomet, where he held various positions over the past nine years including Vice President, Investor Relations and Treasurer and Vice President of Finance for the Americas and Global Product Engines.
Tue, 14 Nov 2017
18:34:00 +0000
Neurocrine Announces Long-Term Results Evaluating INGREZZA® for the Treatment of Adults with Tardive Dyskinesia Published in the Journal of Clinical Psychiatry
SAN DIEGO, Nov. 14, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) announced today that the full manuscript of the long-term safety and efficacy data from the blinded KINECT 3 Phase III extension study evaluating INGREZZA® (valbenazine) capsules for the treatment of adults with tardive dyskinesia (TD) were published in the Journal of Clinical Psychiatry1. The once-daily 80 mg and 40 mg doses of INGREZZA continued to maintain symptom improvement and were generally well-tolerated over long-term dosing in patients with TD, a condition characterized by uncontrollable, abnormal and repetitive movements of the trunk, extremities and/or face. "We are pleased with the long-term data, which demonstrate the ability of INGREZZA to effectively improve the symptoms of tardive dyskinesia with durable response," said Christopher O'Brien, M.D., Chief Medical Officer of Neurocrine Biosciences.
Thu, 09 Nov 2017
21:01:00 +0000
INGREZZA®, First FDA Approved Product for the Treatment of Tardive Dyskinesia, Receives Outstanding Therapeutic Product Award from Prestigious California Life Sciences Association
SAN DIEGO, Nov. 9, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) announced today that INGREZZA® (valbenazine) capsules, the first FDA approved product indicated for the treatment of adults with tardive dyskinesia (TD), a condition characterized by uncontrollable, abnormal and repetitive movements of the trunk, extremities and/or face, was awarded the 2017 Pantheon DiNA Award for Outstanding Therapeutic Product by the California Life Sciences Association (CLSA). CLSA is the state's largest and most influential life sciences advocacy and business leadership organization. CLSA will honor this year's winners at the 2017 Pantheon DiNA Awards ceremony on Friday, November 10, at the Marriott Marquis in San Francisco.
Wed, 08 Nov 2017
18:15:00 +0000
Neurocrine Biosciences to Present at the Jefferies 2017 London Healthcare Conference
Live Audio Webcast Will be on November 16, 2017 SAN DIEGO , Nov. 8, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) will present at the Jefferies 2017 London Healthcare Conference at 11:20 ...
Wed, 08 Nov 2017
03:12:32 +0000
Edited Transcript of NBIX earnings conference call or presentation 1-Nov-17 9:00pm GMT
Q3 2017 Neurocrine Biosciences Inc Earnings Call
Tue, 07 Nov 2017
21:01:00 +0000
Neurocrine to Present Data on the Patient Impact of Tardive Dyskinesia from the RE-KINECT Study at the 2017 Neuroscience Education Institute Congress
SAN DIEGO, Nov. 7, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) today announced that data for INGREZZA® (valbenazine) capsules, the first FDA approved treatment for adults with tardive dyskinesia (TD), will be presented at the 2017 Neuroscience Education Institute Congress to be held November 8-12 in Colorado Springs, Colorado. Data being presented include analyses from the RE-KINECT study, a real-world screening study and registry that describes the presence and impact of involuntary movements in patients taking antipsychotics, as well as pooled data analyses from INGREZZA clinical studies across patient sub-groups. "We are pleased to share findings on the impact of tardive dyskinesia, which is characterized by uncontrollable, abnormal and repetitive movements, on real-world patients," said Chris O'Brien, M.D., Chief Medical Officer of Neurocrine.
Tue, 07 Nov 2017
12:55:27 +0000
Neurocrine stock rockets to a record on sales beat—but can it last?
Neurocrine charged many patients twice the price of the drug in the latest quarter—but it is coming to an end.
Fri, 03 Nov 2017
12:10:00 +0000
Today's Research Reports on Stocks to Watch: Neurocrine Biosciences and Alnylam Pharmaceuticals
NEW YORK, NY / ACCESSWIRE / November 3, 2017 / Neurocrine Biosciences was a big mover on Thursday, even hitting a new high after outstanding third quarter results and impressive INGREZZA sales. Alnylam ...
Fri, 03 Nov 2017
07:00:00 +0000
Stocks Showing Market Leadership: Neurocrine Biosciences Earns 96 RS Rating
Neurocrine Biosciences sees its Relative Strength Rating hit the elite 90-plus level.



"ValueForum is an active, private, online discussion community for stock & bond market investing. In discussion forums divided into finely grained topics, you will find sophisticated investors trading tips, research, and due diligence on value stocks, income investments, forex, market news, and more. Join in - trade ideas, strategies, current news, via our unique message bulletin boards, stock ratings system, and other online tools specifically geared toward our community."

Random member testimonial: "It [ValueForum] has provided me with eye opening information on a wide scale. The collective wisdom of the membership is astounding and somewhat intimidating; but useful input is appreciated pretty universally." more testimonials »

Email / About | Privacy | Terms of Use | How To / FAQ | Msg Ticker | VF Home | My.vf | BDCs.vf | Energy.vf | REITs.vf | TA.vf
 
Nothing in ValueForum.com is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by ValueForum.com. ©2003 - 2017, Powered in part by Ticker TechnologiesContact Us

Stock Market Investing Forum - Trading Tips & Research - Online Message Boards